2 results
Approved WMOWill not start
Part 1 - To determine the efficacy of oral BCX9930 monotherapy administered for 24 weeks, compared to continued complement component 5 (C5) inhibitor therapy, in subjects with paroxysmal nocturnal hemoglobinuria (PNH) with an inadequate response to…
Approved WMOCompleted
The following questions will be addressed in the PARASOL study• Is the proposed study design feasible?,We will set up the study as a randomized pilot study to evaluate if patients are willing and able to participate in a randomized trial, i.e. are…